The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achillion Pharmaceuticals Inc. | COM | 00448Q201 | 5,854 | 1,779,340 | SH | DFND | 3 | 1,779,340 | 0 | 0 | |
| Alexion Pharmaceuticals Inc. | COM | 015351109 | 110,664 | 727,428 | SH | DFND | 2 | 727,428 | 0 | 0 | |
| Alnylam Pharmaceuticals Inc. | COM | 02043Q107 | 31,642 | 471,288 | SH | DFND | 3 | 471,288 | 0 | 0 | |
| Ariad Pharmaceuticals Inc. | COM | 04033A100 | 1,382 | 171,517 | SH | DFND | 3 | 171,517 | 0 | 0 | |
| Celgene Corp | COM | 151020104 | 304,977 | 2,184,649 | SH | DFND | 2 | 2,184,649 | 0 | 0 | |
| Clovis Oncology Inc | COM | 189464100 | 33,817 | 488,188 | SH | DFND | 3 | 488,188 | 0 | 0 | |
| Cubist Pharmaceuticals Inc. | RIGHT 99/99/9999 | 229678123 | 570 | 876,273 | SH | DFND | 3 | 876,273 | 0 | 0 | |
| Endocyte Inc. | COM | 29269A102 | 58,656 | 2,463,522 | SH | DFND | 3 | 2,463,522 | 0 | 0 | |
| Gilead Sciences Inc. | COM | 375558103 | 248,966 | 3,513,496 | SH | DFND | 1 | 3,513,496 | 0 | 0 | |
| Halozyme Therapeutics Inc. | COM | 40637H109 | 71,676 | 5,641,564 | SH | DFND | 3 | 5,641,564 | 0 | 0 | |
| Idenix Pharmaceuticals Inc. | COM | 45166R204 | 7,538 | 1,250,000 | SH | DFND | 3 | 1,250,000 | 0 | 0 | |
| ImmunoGen Inc. | COM | 45253H101 | 47,266 | 3,165,816 | SH | DFND | 3 | 3,165,816 | 0 | 0 | |
| Incyte Corp | COM | 45337C102 | 221,240 | 4,133,790 | SH | DFND | 3 | 4,133,790 | 0 | 0 | |
| Infinity Pharmaceuticals Inc. | COM | 45665G303 | 15,466 | 1,300,737 | SH | DFND | 3 | 1,300,737 | 0 | 0 | |
| Isis Pharmaceuticals Inc. | COM | 464330109 | 272,289 | 6,301,526 | SH | DFND | 3 | 6,301,526 | 0 | 0 | |
| Medivation Inc. | COM | 58501N101 | 93,961 | 1,459,706 | SH | DFND | 3 | 1,459,706 | 0 | 0 | |
| Neurocrine Biosciences Inc. | COM | 64125C109 | 48,244 | 2,996,552 | SH | DFND | 3 | 2,996,552 | 0 | 0 | |
| Pharmacyclics Inc. | COM | 716933106 | 63,794 | 636,542 | SH | DFND | 2 | 636,542 | 0 | 0 | |
| Puma Biotechnology Inc. | COM | 74587V107 | 12,288 | 117,991 | SH | DFND | 3 | 117,991 | 0 | 0 | |
| Regeneron Pharmaceuticals Inc. | COM | 75886F107 | 66,962 | 223,000 | SH | DFND | 2 | 223,000 | 0 | 0 | |
| Synageva BioPharma Corp. | COM | 87159A103 | 77,988 | 939,957 | SH | DFND | 3 | 939,957 | 0 | 0 | |
| Tesaro Inc. | COM | 881569107 | 17,823 | 604,582 | SH | DFND | 3 | 604,582 | 0 | 0 | |
| Theravance Inc. | COM | 88338T104 | 27,482 | 888,244 | SH | DFND | 3 | 888,244 | 0 | 0 | |
| Vertex Pharmaceuticals Inc. | COM | 92532F100 | 99,322 | 1,404,445 | SH | DFND | 3 | 1,404,445 | 0 | 0 | |